DB:4QG

Stock Analysis Report

Executive Summary

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform.

Risk Analysis

Earnings have declined by -11.89% per year over past 5 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Does not have meaningful revenue (NOK10M)



Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has PCI Biotech Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4QG has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

2.2%

4QG

1.5%

DE Biotechs

0.5%

DE Market


1 Year Return

156.6%

4QG

5.8%

DE Biotechs

15.5%

DE Market

Return vs Industry: 4QG exceeded the German Biotechs industry which returned 5.3% over the past year.

Return vs Market: 4QG exceeded the German Market which returned 17.1% over the past year.


Shareholder returns

4QGIndustryMarket
7 Day2.2%1.5%0.5%
30 Day-1.7%-2.9%1.4%
90 Dayn/a11.2%5.3%
1 Year156.6%156.6%6.0%5.8%19.2%15.5%
3 Yearn/a60.1%58.3%15.7%5.5%
5 Yearn/a16.1%13.7%27.3%10.1%

Price Volatility Vs. Market

How volatile is PCI Biotech Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is PCI Biotech Holding undervalued compared to its fair value and its price relative to the market?

9.25x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4QG's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 4QG's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 4QG is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 4QG is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4QG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4QG is overvalued based on its PB Ratio (8.9x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is PCI Biotech Holding forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

39.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PCI Biotech Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has PCI Biotech Holding performed over the past 5 years?

-11.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4QG is currently unprofitable.

Growing Profit Margin: 4QG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 4QG is unprofitable, and losses have increased over the past 5 years at a rate of -11.9% per year.

Accelerating Growth: Unable to compare 4QG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4QG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: 4QG has a negative Return on Equity (-24.43%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is PCI Biotech Holding's financial position?


Financial Position Analysis

Short Term Liabilities: 4QG's short term assets (NOK302.1M) exceed its short term liabilities (NOK28.2M).

Long Term Liabilities: 4QG's short term assets (NOK302.1M) exceed its long term liabilities (NOK1.2M).


Debt to Equity History and Analysis

Debt Level: 4QG is debt free.

Reducing Debt: 4QG has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 4QG has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 4QG's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4QG has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 4QG has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -16.3% each year


Next Steps

Dividend

What is PCI Biotech Holding's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.5%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 4QG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 4QG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4QG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4QG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4QG's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of PCI Biotech Holding's salary, the management and board of directors tenure and is there insider trading?

6.3yrs

Average management tenure


CEO

Per Walday (59yo)

11.8yrs

Tenure

kr2,175,000

Compensation

Dr. Per Walday, Ph.D., has been the Chief Executive Officer at PCI Biotech AS since 2008. Dr. Walday has been the Chief Executive Officer at PCI Biotech Holding ASA since April 2008 and served as its Manag ...


CEO Compensation Analysis

Compensation vs Market: Per's total compensation ($USD245.01K) is below average for companies of similar size in the German market ($USD638.09K).

Compensation vs Earnings: Per's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

6.3yrs

Average Tenure

59yo

Average Age

Experienced Management: 4QG's management team is seasoned and experienced (6.3 years average tenure).


Board Age and Tenure

2.7yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 4QG's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Buy€33,96818 Oct 19
Lars Viksmoen
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares12,966
Max Price€2.62
Sell€33,96818 Oct 19
Lars Viksmoen
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares12,966
Max Price€2.62
Buy€10,70629 Aug 19
Hilde Furberg
EntityIndividual
Role
Member of the Board of Directors
Director
Shares4,000
Max Price€2.68

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 47.9%.


Management Team

  • Anders Høgset (65yo)

    Chief Scientific Officer

    • Tenure: 12yrs
    • Compensation: kr1.30m
  • Per Walday (59yo)

    Chief Executive Officer

    • Tenure: 11.8yrs
    • Compensation: kr2.18m
  • Ronny Skuggedal (43yo)

    Chief Financial Officer

    • Tenure: 6.3yrs
    • Compensation: kr1.65m
  • Kristin Eivindvik (58yo)

    Chief Development Officer

    • Tenure: 0.9yrs
    • Compensation: kr1.32m
  • Hans Olivecrona (61yo)

    Chief Medical Officer

    • Tenure: 2.3yrs
    • Compensation: kr1.19m

Board Members

  • Hilde Furberg (53yo)

    Director

    • Tenure: 0.7yrs
    • Compensation: kr185.00k
  • Hans Bøhn (64yo)

    Chairman

    • Tenure: 3.7yrs
    • Compensation: kr300.00k
  • Kjetil Taskén (54yo)

    Member of Scientific Advisory Committee

    • Compensation: kr185.00k
  • Lars Viksmoen (70yo)

    Independent Director

    • Tenure: 3.7yrs
    • Compensation: kr185.00k
  • Christina Herder (58yo)

    Independent Director

    • Tenure: 4.7yrs
    • Compensation: kr185.00k
  • Andrew Hughes (55yo)

    Independent Director

    • Tenure: 1.7yrs
  • Sjoerd van der Burg

    Member of Scientific Advisory Committee

    • Tenure: 1yrs

Company Information

PCI Biotech Holding ASA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PCI Biotech Holding ASA
  • Ticker: 4QG
  • Exchange: DB
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr2.579b
  • Listing Market Cap: kr258.985m
  • Shares outstanding: 37.27m
  • Website: https://www.pcibiotech.com

Number of Employees


Location

  • PCI Biotech Holding ASA
  • Ullernchausséen 64
  • Oslo
  • Oslo
  • 379
  • Norway

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PCIBOB (Oslo Bors)YesOrdinary SharesNONOKJun 2008
4QGDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 2008
0JGLLSE (London Stock Exchange)YesOrdinary SharesGBNOKJun 2008
PCIBOBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBNOKJun 2008

Biography

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. Its PCI technology induces triggered endosomal release, which enhances various therapeutic modalities, such as small molecules, vaccines, and nucleic acids. The company’s lead product candidate is Amphinex, a photosensitiser fimaporfin. Its PCI technology is applied to three distinct anticancer paradigms, including fimaCHEM, a Phase I/II clinical study in bile duct cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination; and fimaNAc, a nucleic acid therapeutics delivery technology. The company has collaborative research programs with Phio Pharmaceuticals; BioNTech AG; eTheRNA immunotherapies NV; and Bavarian Nordic A/S. PCI Biotech Holding ASA was founded in 2000 and is headquartered in Oslo, Norway. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/01/22 21:20
End of Day Share Price2020/01/22 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.